SAR444336

Phase 2Small molecule

Sanofi

SAR444336 is one of 5 small molecule programs targeting Microscopic Colitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Microscopic ColitisRecruiting

Microscopic ColitisPhase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Microscopic Colitis

#DrugCompanyPhaseTrials

Pulmicort

SSalix

Approved

1 2

Xifaxan

SSalix

Phase 2

1 3

SAR444336

Sanofi

Phase 2

1 4

Bismuth

SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Preclinical

1 5

Fiber

KKing Saud University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Microscopic Colitis

NCT07156175

Clinical

Trials by Indication[1]

Microscopic Colitis1 trial

A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission

Recruiting· Sanofi logo

Sanofi·Phase 2·NCT07156175·54 enrolled

Adult1 trial

Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single and Repeated Doses of SAR444336 in Healthy Adult Participants

Completed· Sanofi logo

Sanofi·Phase 1·NCT05876767·76 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for SAR444336. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SAR444336 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SAR444336. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Sanofi

SAR444336

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Microscopic Colitis1 trial

Adult1 trial

References

Drug Info

Quick Facts

Related News